Clinical Trial

PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to test the effects of PHENOGENE-1A, which is the treatment under investigation in this study. This research will investigate if PHENOGENE-1A can help people with ALS by measuring their function using the ALS Functional Rating Scale Revised (ALSFRS-R), measuring lung function using pulmonary function tests (PFTs), such as forced vital capacity (FVC), and measuring neuro-inflammatory biomarkers in the blood.
Protocol Amendment History 3 changes
notable Primary completion moved earlier: 2027-11 -> 2027-03 2026-06-10
minor Completion moved earlier: 2028-03 -> 2027-06 2026-06-10
notable Trial sites expanded: 12 -> 17 locations 2026-04-02
Trial Details
NCT Number NCT07142291
Lead Sponsor PhenoNet, Inc.
Conditions Amyotrophic Lateral Sclerosis (ALS)
Enrollment 105 participants
Start Date 2025-11-25
Primary Completion 2027-03 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-23